Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.49 |
| ▸ | CDK1 | P06493 | 14/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 14/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCND2 | P30279 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587928 | 0.89 | AURKA (0.49) | AURKACDK1AURKBEGFRCDK4 | |
| SCHEMBL14957671 | 0.85 | JAK3 (0.46) | EGFRCDK4CCND1CCND2CCND3 | |
| SCHEMBL12174908 | 0.82 | JAK1 (0.53) | AURKACDK1AURKBJAK3JAK2 | |
| SCHEMBL12361587 | 0.81 | CDK2 (0.42) | EGFRCDK4CCND1CCND2CCND3 | |
| SCHEMBL2595420 | 0.78 | AURKA (0.64) | AURKACDK1AURKBJAK2JAK1 | |
| SCHEMBL2585170 | 0.78 | AURKA (0.64) | AURKACDK1AURKBJAK2JAK1 | |
| SCHEMBL12639344 | 0.77 | CDK4 (0.69) | AURKACDK1AURKBEGFRCDK4 | |
| SCHEMBL1355734 | 0.77 | CDK4 (0.69) | AURKACDK1AURKBEGFRCDK4 | |
| SCHEMBL14957826 | 0.75 | JAK3 (0.46) | AURKACDK1AURKBEGFRJAK3 | |
| SCHEMBL343480 | 0.74 | AURKA (0.58) | AURKACDK1AURKBCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | AURKA 406/4885CDK1 26/4885AURKB 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.